V CompBrief BY VELARION

Executive Vice President and Chief Financial Officer · MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Mardi Dier

Mardi Dier, Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals, Inc., received total compensation of $6,085,089 for fiscal year 2025. This amount included a base salary of $566,042, a cash bonus or incentive of $554,165, and stock-based compensation of $4,875,536.

FY2025 is the first fiscal year CompBrief holds for Mardi Dier as a named executive officer of MADRIGAL PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$6,085,089

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Mardi Dier compensation by year

MADRIGAL PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as MADRIGAL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$566,042
Bonus$0
Stock awards$3,561,539
Option awards$1,313,997
Non-equity incentive$554,165
Pension and deferred compensation$0
All other$89,346
Total$6,085,089

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 28, 2026, accession 0001308179-26-000352, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU17,750$10,336,535—
PSU7,568$4,407,149—
RSU6,656$3,876,055—
RSU3,784$2,203,575—
Option6,374—$347.28
Option7,511—$251.63

Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

MADRIGAL PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Bill SiboldPresident and Chief Executive Officer$19,206,341
David SoergelExecutive Vice President and Chief Medical Officer$9,190,678
Rebecca TaubSenior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer$6,868,016
Mardi Dier · this pageExecutive Vice President and Chief Financial Officer$6,085,089
Carole HuntsmanExecutive Vice President and Chief Commercial Officer$5,441,736
Shannon KelleyExecutive Vice President and Chief Legal Counsel$5,179,352

The full MADRIGAL PHARMACEUTICALS compensation record

free company brief
MADRIGAL PHARMACEUTICALS, INC. (MDGL) — free Compensation Briefevery named executive and director, board pay, say-on-pay, the peer group

This page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MADRIGAL PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

Open the Daily Digestfree · newest disclosuresFull report & benchmarkingExecutive Compensation Report · $1,500
How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy